– The dose range for Rosuvastatin is 5 to 40 mg orally once daily. The usual starting dose is 10-20 mg.

– Rosuvastatin can be administered as a single dose at any time of day, with or without food.

– When initiating Rosuvastatin therapy or switching from another HMG-CoA reductase inhibitor therapy, the appropriate Rosuvastatin starting dose should first be utilized, and only then titrated according to the patient’s response and individualized goal of therapy.

– After initiation or upon titration of Rosuvastatin, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly.

– Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 to 17 years of age): The usual dose range of Rosuvastatin is 5-20 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population). Adjustments should be made at intervals of 4 weeks or more.

– Homozygous Familial Hypercholesterolemia

The recommended starting dose of Rosuvastatin is 20 mg once daily. Response to therapy should be estimated from preapheresis LDL-C levels.

– Use with Cyclosporine, Lopinavir/Ritonavir or Atazanavir/Ritonavir: In patients taking cyclosporine, the dose of Rosuvastatin should be limited to 5 mg once. In patients taking a combination of lopinavir and ritonavir or atazanavir and ritonavir, the dose of Rosuvastatin should be limited to 10 mg once daily.

– Dosage in Patients with Severe Renal Impairment

For patients with severe renal impairment (CL_cr<30 mL/min/1.73 m²) not on hemodialysis, dosing of Rosuvastatin should be started at 5 mg once daily and not exceed 10 mg once daily.